Efficacy and Safety of Evening Administration of Controlled-Delivery XXXX Capsules in Chronic Stable Angina @entity1 .

@entity1 @entity308 @entity3988 @entity23 @entity951
The safety and efficacy of @entity23 ( @entity23 ) once-a-day formulation of @entity3988 administered in the evening, at a dose of 240 mg, was assessed in 37 @entity1 with stable @entity951 . A double-blind, placebo-controlled, randomized, crossover protocol was used. Following a 4-day washout period, @entity1 entered a 5--7-day single-blind placebo run-in period during which qualification and reproducibility exercise treadmill tests (ETTs) were performed 24 h postdose. Eligible @entity1 were randomized in a double-blind fashion, to either @entity23 @entity3988 or to placebo for a 7--10-day treatment period. They then entered a 5--7-day single-blind washout period, after which they received the alternate treatment for another 7 to 10 days. ETTs were performed at the end of each treatment period. Compared to placebo, evening administration of @entity23 @entity3988 produced a marked improvement of the time to ETT termination, time to onset of @entity951 , and time to 1 mm ST @entity308 . In addition, the number of @entity951 recorded in @entity1 diaries was reduced compared to placebo. Incidence of adverse events was comparable with @entity23 @entity3988 and placebo. We conclude that evening administration of @entity23 @entity3988 is highly effective and safe in the treatment of stable @entity951 .
